Evidence map›Paper›PMID 32344180›Full record

ArticleCellular and molecular gastroenterology and hepatology2020

Genome-Scale Analysis Identifies Novel Transcript-Variants in Esophageal Adenocarcinoma.

B P D Purkayastha, E R Chan, D Ravillah, L Ravi, R Gupta, M I Canto, J S Wang, N J Shaheen, J E Willis, A Chak and 2 more

Abstract readLetter
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

B P D PurkayasthaDivision of General Medical Sciences-Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
E R ChanInstitute for Computational Biology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
D RavillahDivision of General Medical Sciences-Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
L RaviDivision of General Medical Sciences-Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
R GuptaDivision of Gastroenterology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
M I CantoDivision of Gastroenterology and Hepatology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland.
J S WangDivision of Gastroenterology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
N J ShaheenCenter for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina.
J E WillisDepartment of Pathology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
A ChakDivision of Gastroenterology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
V VaradanDivision of General Medical Sciences-Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio.
K GudaDivision of General Medical Sciences-Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Pathology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio. Electronic address: gkishore@yahoo.com.

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5M
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and PreventionP50CA150964 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2011 to 2022
$24.6M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Theresa Torres Pizarro · 2015 to 2026
$15.6M
Whole Exome Approaches for Esophageal Adenocarcinoma Susceptibility GenesU54CA163060 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHAK, AMITABH, GUDA, KISHORE · 2011 to 2022
$14.0M
Translational Research Enhancement CoreP30DK089502 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ZACHOS, NICHOLAS CONSTANTINE · 2011 to 2020
$12.0M
Identify and validate novel epigenetic molecular markers for colorectal neoplasmU01CA152756 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GRADY, WILLIAM MALLORY, GUDA, KISHORE · 2010 to 2021
$6.7M
EPHA6 as a novel candidate driver gene in colon cancerR01CA204549 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GUDA, KISHORE · 2016 to 2020
$1.8M
Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative TherapyK24DK100548 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHAHEEN, NICHOLAS J · 2013 to 2017
$896k
Systems biology frameworks to unravel mechanisms driving complex disordersK25DK115904 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI VARADAN, VINAY · 2019 to 2021
$515k
NCI NIH HHS P30 CA043703NCI NIH HHS P50 CA150964NCI NIH HHS R01 CA204549NCI NIH HHS U01 CA152756NCI NIH HHS U54 CA163060NIDDK NIH HHS K24 DK100548NIDDK NIH HHS K25 DK115904NIDDK NIH HHS P30 DK034987NIDDK NIH HHS P30 DK089502NIDDK NIH HHS P30 DK097948
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alternative SplicingAdenocarcinomaAdultAgedAged, 80 and overBiopsyCarcinogenesisCell MovementCollagen Type XDatasets as TopicEsophageal MucosaEsophageal NeoplasmsFemaleGene Knockdown TechniquesHEK293 CellsHumansCOL10A1 protein, humanCollagen Type XProtein Isoforms

Identifiers

PMID32344180
PMCPMC7474160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.